Clinical Trials Logo

Filter by:
NCT ID: NCT02946268 Withdrawn - Pain Clinical Trials

Optimal Volume, Rate, and Interval of Bolus Nerve Catheters for Shoulder Surgery

Start date: February 21, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the ideal delivery of local anesthetics for pain control when using continuous interscalene peripheral nerve catheters for shoulder surgery. The study will be conducted in three stages. In the first stage the ideal bolus volume of ropivacaine will be determined. In the second stage the optimal rate of delivery of the bolus (infusion rate) will be determined. Finally, once both the ideal volume and infusion rate has been determined, the optimal interval between boluses of local anesthetic will be determined.

NCT ID: NCT02945839 Withdrawn - Migraine Clinical Trials

Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department

Start date: December 28, 2016
Phase: Phase 4
Study type: Interventional

Collectively, evidence shows that a combination of medication and behavioral therapy is most effective for migraine care. The ED is a critical point of contact with the health care system for many migraine patients; in current practice, it is a missed opportunity to initiate and establish a comprehensive migraine management paradigm. Behavioral headache treatments (e.g., progressive muscle relaxation (PMR), biofeedback, cognitive-behavioral therapy (CBT)) are effective migraine treatment options that are essentially free of side effects. PMR has also been successful as a technique that patients can do independently. Studies have shown that combination pharmacological-behavioral therapy is most effective for migraine treatment. Several aspects of this study are innovative, including: 1. Initiation of preventive medication in a timely manner for migraineurs who present to the ED. 2. Introduction of PM+PMR in the ED at a time that can serve as a teachable moment. 3. Introduction of a smartphone application-based product (a minimal contact based behavioral therapy) in the ED setting to reduce headache disability, frequency, and intensity.

NCT ID: NCT02944357 Withdrawn - Clinical trials for Infiltrating Bladder Urothelial Carcinoma

Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery

Start date: November 2016
Phase: N/A
Study type: Interventional

This pilot clinical trial studies how well gemcitabine hydrochloride, cisplatin, and AGS-003-BLD work in treating patients with bladder cancer that has spread to the muscle and who are undergoing surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells. Giving gemcitabine hydrochloride, cisplatin, and AGS-003-BLD before surgery may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery.

NCT ID: NCT02943616 Withdrawn - Clinical trials for Ischemic Heart Disease

ABSORB Post-Approval Clinical Study

Start date: August 2017
Phase: N/A
Study type: Interventional

The ABSORB Post-Approval Clinical Study is a prospective, open-label, multi-center, single-arm, non-randomized trial to evaluate the safety of the use of ABSORB in a real-world setting following commercial physician training'and to observe the effectiveness of commercial physician training on appropriate vessel sizing.

NCT ID: NCT02943603 Withdrawn - Adenocarcinoma Clinical Trials

A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach

Start date: January 2017
Phase: Phase 2
Study type: Interventional

This research study is being down to find what, effects, good and/or bad, adding Pembrolizumab to standard chemotherapy mFOLFOX before and after surgery have on the patient and the patient's cancer.

NCT ID: NCT02942212 Withdrawn - Smoking Cessation Clinical Trials

Health Literacy and Smoking Cessation in Low-SES Diverse Smokers - Project HALT II

Start date: December 14, 2018
Phase: Early Phase 1
Study type: Interventional

In-Depth Interviews: The goal of this research study is to learn about ways to help people might have trouble understanding health information quit smoking. Pilot Study: The goal of this research study is to test 2 different approaches, Standard Treatment (ST) and Helping Adults with Health Literacy Trouble (HALT) tailored treatment, for helping smokers who might have trouble understanding health information with quitting smoking.

NCT ID: NCT02941601 Withdrawn - Clinical trials for Metastatic Squamous Non-Small Cell Lung Cancer

A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

Start date: November 2016
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the effectiveness and safety of gemcitabine-carboplatin plus necitumumab in chemotherapy-naïve participants with locally advanced or metastatic squamous non-small cell lung cancer.

NCT ID: NCT02940587 Withdrawn - Venous Leg Ulcers Clinical Trials

Effectiveness of Aurix Therapy in Venous Leg Ulcers

Start date: February 2015
Phase: Phase 4
Study type: Interventional

The aim of this trial is to demonstrate the effectiveness of complete wound healing in a prospective, open-label, randomized trial in which venous leg ulcers (VLU)n will be treated using Aurix and compared to patients receiving undefined Usual and Customary Care (UCC)

NCT ID: NCT02940236 Withdrawn - General Surgery Clinical Trials

Gastric Volumes After Oral Multimodal Analgesia in the Pre-operative Setting: A Prospective Case Series

Start date: October 2016
Phase:
Study type: Observational

To assess possible risk of aspiration with pre-operative oral medications taken with "sips" of water (100ml).

NCT ID: NCT02939859 Withdrawn - Multiple Sclerosis Clinical Trials

Use of Cellular Stromal Vascular Fraction in Multiple Sclerosis,Autoimmune, Inflammatory, Neurologic Conditions

cSVF
Start date: December 15, 2018
Phase: Phase 1
Study type: Interventional

Purpose of study is to determine safety and efficacy of use of autologous Adipose-Derived cellular Stromal Vascular Fraction (AD-cSVF) suspended in Normal Saline and delivered via intravascular system of quality of life and alteration of documented Muscular Sclerosis (MS) and related neurodegenerative patients. It is believed that the heterogeneous cell population which includes multipotent stem/stromal cells are capable of immune modulation/inflammatory modulation properties. Exam of disease progression and quality of life changes will be evaluated.